Antibodies
27 September 2023
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease27 September 2023
Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in Australia26 September 2023
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)26 September 2023
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results26 September 2023
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody.26 September 2023
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®26 September 2023
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe23 September 2023
Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC22 September 2023
Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function21 September 2023
Fresenius Kabi’s biosimilar Tyenne®* becomes first tocilizumab biosimilar approved by the European Commission21 September 2023
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers20 September 2023
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)19 September 2023
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)19 September 2023
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)19 September 2023
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®19 September 2023
Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-10117 September 2023
PSMA: a binding target for delivery of payloads – a pipeline reviewNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports